Trial Profile
Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs NN 9926 (Primary) ; NN 9926 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 23 May 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 23 May 2012 Actual patients number is 55 as reported by ClinicalTrials.gov.
- 23 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.